Photosensitization Study in Androgenetic Alopecia
NCT02791243
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
58
Enrollment
INDUSTRY
Sponsor class
Conditions
Androgenetic Alopecia
Interventions
DRUG:
Finasteride 0.25%
DRUG:
Placebo for Finasteride 0.25%
DRUG:
Negative Control
Sponsor
Polichem S.A.